Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459232
Status:
COMPLETED
Last Update Posted:
2024-06-14
First Post:
2024-06-10
Brief Title:
Characteristics Adherence and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Baseline Characteristics Adherence and Persistence Among Multiple Sclerosis Patients Treated With FDA-approved Disease-Modifying Therapies
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This retrospective observational cohort study used administrative claims data contained in the International Business Machines IBM Truven Marketscan Research Databases to describe demographic clinical and treatment characteristics in patients with multiple sclerosis MS who were initiated on siponimod and other Food and Drug Administration FDA-approved disease-modifying therapies DMTs The study time period was from March 2018 through June 2020 most recent available data and included a 1-year baseline period and a variable-length follow-up period a minimum of 6 months follow-up required for post-index outcomes The index date was defined as the date of the first claim for siponimod or other MS-specific treatment on or after March 2019
The data analysis was performed on a combination of early view and standard view data The initial data analysis was from Standard Marketscan data used for patients with index data prior to the year 2019 Both standard view and early view data were used for patients indexed after January 1 2019 The early view data provided additional visibility as it contains an additional 2 quarters of data compared to standard data
The data analysis was performed on a combination of early view and standard view data The initial data analysis was from Standard Marketscan data used for patients with index data prior to the year 2019 Both standard view and early view data were used for patients indexed after January 1 2019 The early view data provided additional visibility as it contains an additional 2 quarters of data compared to standard data
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None